2 active not recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 2 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Metastases: new trials by email Literature Review of Metastases trials Research Report on Metastases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC Sacituzumab tirumotecan, Anlotinib - NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC Stage IIIB~IV | Phase 2 | Active not recruiting | Nanfang Hospital, Southern Medical University | 38 | 2025-08-13 | 2026-07-14 |
| Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin iCasp9M28z T cell infusions, cyclophosphamide, pembrolizumab - Malignant Pleural Disease, Mesothelioma | Phase 1 / Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 113 | 2015-05-01 | 2026-07-22 |
Neoplasm Metastasis (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1) · Mesothelioma (1)
Lung Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2) · Adenoma (1) · Breast Diseases (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Lung Neoplasms (1) · Neoplasms by Histologic Type (1)
Cyclophosphamide (1) · anlotinib (1) · pembrolizumab (1)
Memorial Sloan Kettering Cancer Center (1) · Nanfang Hospital, Southern Medical University (1)
China (1) · United States (1)